方法：选取2013-06/2016-02在北京航天中心医院眼科因糖尿病继发黄斑水肿(DME)和视网膜静脉阻塞继发黄斑水肿(RVO-ME)收治入院，并符合本研究纳入及排除标准的患者35例38眼，其中DME 23眼，RVO-ME 15眼。患眼接受玻璃体腔雷珠单抗(0.5mg/0.05mL)注射治疗，治疗前和治疗后1、3d，1wk、1mo定期门诊回访观察最佳矫正视力(BCVA)、黄斑中心凹厚度(CRT)、眼压。比较雷珠单抗治疗DME及RVO-ME前后的疗效。

结果：DME组及RVO-ME组治疗后1、3d，1wk的BCVA均较治疗前提高，差异均有统计学意义(P<0.05)，而两组1mo的BCVA与治疗前相比差异均无统计学意义(P>0.05)。DME组及RVO-ME组治疗后1、3d，1wk，1mo的CRT均较治疗前明显改善，差异均有统计学意义(P<0.05)。在BCVA及CRT方面比较，雷珠单抗对于RVO-ME及 DME疗效差异无统计学意义(P >0.05)。

结论：玻璃体腔注射雷珠单抗对DME及RVO-ME的治疗均安全有效。

METHODS: Thirty-eight eyes of thirty-five patients was retrospectively evaluated, twenty-three with ME caused by DM and fifteen with RVO, who received intravitreal ranibizumab(0.5mg/0.05ml)and were followed up for at least a month., The best corrected visual acuity(BCVA), central retinal thickness(CRT)and intraocular pressure(IOP)were followed up at 1, 3d, 1wk and 1mo respectively. The effect of the DME and RVO-ME were compared.

RESULTS: DME and RVO- ME group after treatment in 1, 3d, 1wk, the BCVA were obviously improved, and the differences were statistically significant(P<0.05). But compared the BCVA in 1mo with before showed no statistically significant difference(P>0.05). DME and RVO-ME group after treatment in 1, 3d, 1wk and 1mo, CRT was obviously improved, and the differences were statistically significant(P<0.05). The BCVA and CRT of treatment showed no statistically significant difference between DME with RVO-ME(P>0.05).

CONCLUSION: Bevacizumab intravitreal injection for ME caused by DM and RVO was safe and effective.